Forte Biosciences, Inc. (FBRX)
NASDAQ: FBRX · Real-Time Price · USD
5.88
-0.70 (-10.64%)
At close: Apr 4, 2025, 4:00 PM
6.83
+0.95 (16.22%)
After-hours: Apr 4, 2025, 5:30 PM EDT

Forte Biosciences Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2018 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2018 - 2019
Net Income
-35.48-31.48-13.88-21.71-46.49
Upgrade
Depreciation & Amortization
0.040.01-0.040.05
Upgrade
Asset Writedown & Restructuring Costs
---0.0630.89
Upgrade
Loss (Gain) From Sale of Investments
-0.16-0.13---
Upgrade
Stock-Based Compensation
3.13.284.014.210.96
Upgrade
Change in Accounts Payable
3.020.270.21-0.29-0.37
Upgrade
Change in Other Net Operating Assets
-1.26-0.661.471.01-3.46
Upgrade
Operating Cash Flow
-30.75-28.71-8.19-16.68-18.42
Upgrade
Capital Expenditures
-0.04-0.09---
Upgrade
Cash Acquisitions
----3.58
Upgrade
Investment in Securities
-35.960.14---
Upgrade
Investing Cash Flow
-35.990.05--3.58
Upgrade
Issuance of Common Stock
53.0124.747.240.0666.96
Upgrade
Repurchase of Common Stock
-0.04-0.06---
Upgrade
Other Financing Activities
-1.12---0.11-0.29
Upgrade
Financing Cash Flow
51.8624.687.24-0.0466.67
Upgrade
Net Cash Flow
-14.88-3.98-0.94-16.7251.83
Upgrade
Free Cash Flow
-30.78-28.79-8.19-16.68-18.42
Upgrade
Free Cash Flow Per Share
-10.56-22.80-11.77-29.85-62.59
Upgrade
Levered Free Cash Flow
-19.24-17.4-3.18-9.02-8.1
Upgrade
Unlevered Free Cash Flow
-19.24-17.4-3.18-9.02-8.1
Upgrade
Change in Net Working Capital
-3.640.3-1.49-0.160.22
Upgrade
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q